Free Design Audit Available - Click Here for Details

Axonics wins CE mark for 4th-gen rechargeable sacral neuromod system

Axonics (Nasdaq:AXNX) announced today that it received CE mark approval for its R20 rechargeable sacral neuromodulation (SNM) system.

The implantable system provides therapy for patients suffering from overactive bladder or fecal incontinence. Axonics won FDA approval for this generation of the R20 in January 2023. The R20 neurostimulator uses the same small 5cc form factor as the previous-generation R15. It pairs with the same tined lead and intuitive patient remote control. It also features enhanced programming capabilities with expanded MRI labeling.

R20 has a functional life in the body of at least 20 years and reduces charging frequency to every 6-10 months for just one hour.

Axonics expects to begin selling R20 to European customers in mid-April.

Sign up for Blog Updates